Phase II Study of Panitumumab in Combination With Irinotecan for Malignant Gliomas.
Phase of Trial: Phase II
Latest Information Update: 03 Sep 2013
At a glance
- Drugs Irinotecan (Primary) ; Panitumumab (Primary)
- Indications Glioblastoma; Gliosarcoma
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 04 Dec 2012 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 11 Oct 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.